Please login to the form below

Not currently logged in
Email:
Password:

Havas PR appoints new director of health and wellness

Louise Stone has worked with Lexus PR, Nexus Communications and Good Relations

Havas-PR,-Louise-Stone

Havas PR has strengthened its London healthcare offering with the hiring of Louise Stone as director.

During her 18 year PR career, Stone has worked with agencies including Lexus PR, Nexus Communications and Good Relations and has managed clients such as Boots, Unilever, P&G and GSK.

In this new role she will provide senior client consultancy and generate new business in the health and wellness sectors.

"I am very excited by the unique opportunities at Havas PR, as we work closely with our colleagues across the wider Havas business to offer neutral communications solutions for clients here in the UK and on a European and global scale," Stone said.

"Healthcare PR has traditionally been slow on the take up of digital and social communications, but working as an integrated team at Havas means that we can offer clients the reassurance that we are using the right channel to deliver measurable results and affect behaviour or have a positive impact on sales".

She will be reporting to Steve Marinker, who joined the agency as managing director in September last year.

13th February 2013

From: Marketing

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics